Patents Examined by Stuart W. Snyder
  • Patent number: 9913895
    Abstract: The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and SIV, or between HIV and FIV. In another embodiment, the epitope is one that is conserved between HIV, SIV, and FIV.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: March 13, 2018
    Inventor: Janet K. Yamamoto
  • Patent number: 9907843
    Abstract: The invention relates to a recombinant novirhabdovirus expressing a chimeric protein comprising the sequence of an antigen of interest flanked, at the N-terminus, by a signal peptide, and at the C-terminus, by a polypeptide comprising at least one portion of the transmembrane domain of a rhabdovirus G protein. Said recombinant novirhabdovirus can be used especially for inducing an immune response to the antigen of interest.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 6, 2018
    Assignee: Institut National de la Recherche Agronomique
    Inventors: Michel Bremont, Angella Nzonza
  • Patent number: 9879281
    Abstract: Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 30, 2018
    Inventors: Ho Sun Son, Sang Gu Yeo, Sang Won Lee
  • Patent number: 9879230
    Abstract: Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5? and 3? long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 30, 2018
    Inventors: Yahia Chebloune, Delphine Aldebert, Géraldine Arrode-Bruses
  • Patent number: 9879068
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 30, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • Patent number: 9868777
    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: January 16, 2018
    Assignees: Merck Sharp & Dohme Corp., Board of Regents of the University of Texas System
    Inventors: Tong-Ming Fu, Dai Wang, Zhiqiang An
  • Patent number: 9862927
    Abstract: Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-?), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 9, 2018
    Assignees: Baylor Research Institute, Agence Nationale de Recherches Sur le Sida Et Les Hepatitis Virales
    Inventors: Jacques F. Banchereau, Monica Montes, Anna Karolina Palucka, Louis M. Sloan, Yves Levy
  • Patent number: 9861693
    Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 9, 2018
    Assignee: Emory University
    Inventors: Rama Rao Amara, June R. Scott, Bernard Quigley, Venkateswarlu Chamcha
  • Patent number: 9862933
    Abstract: The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: January 9, 2018
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shengxiang Ge, Tingdong Li, Qingshun Guo, Feihai Xu, Jun Zhang, Ningshao Xia
  • Patent number: 9863948
    Abstract: The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: January 9, 2018
    Assignee: BIOMERIEUX
    Inventor: Frédéric Bedin
  • Patent number: 9855329
    Abstract: Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 2, 2018
    Assignees: Los Alamos National Security, LLC, Dana-Farber Cancer Institute, Duke University
    Inventors: Bette T. M. Korber, S. Gnanakaran, Simon Perkins, Joseph Sodroski, Barton Haynes
  • Patent number: 9841425
    Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: December 12, 2017
    Assignee: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Patent number: 9816147
    Abstract: The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: November 14, 2017
    Inventors: Barbara A. Israel, Nicholas Abbott, Christopher Murphy, Karla Anhalt, Syrus Soltaninassab, Doug Hansmann, Bharat Raj Acharya
  • Patent number: 9783787
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: October 10, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Patent number: 9783594
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: October 10, 2017
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 9750800
    Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: September 5, 2017
    Assignee: Sanofi Pasteur SA
    Inventors: Virginie Fabre, Celine Rocca, Pierre Riffard, Eric Calvosa
  • Patent number: 9744229
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: August 29, 2017
    Inventors: David B. Weiner, Mathew P. Morrow
  • Patent number: 9745352
    Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: August 29, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
  • Patent number: 9738688
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 22, 2017
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
  • Patent number: 9732327
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser